{"title":"吉利德将与Assembly Bio合作","authors":"None Laura Howes","doi":"10.1021/cen-10135-buscon16","DOIUrl":null,"url":null,"abstract":"Gilead Sciences is paying Assembly Biosciences $100 million for first refusal on all Assembly’s programs. The deal comprises $84.8 million in cash, plus $15.2 million in equity investment. Rather than buying the antiviral R&D firm outright, Gilead will integrate the company’s expertise in the herpes virus and hepatitis B and D. Assembly Bio will be responsible for early-stage research and development; if Gilead opts into any programs, it will take on all further work.","PeriodicalId":9517,"journal":{"name":"C&EN Global Enterprise","volume":"50 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Gilead to partner with Assembly Bio\",\"authors\":\"None Laura Howes\",\"doi\":\"10.1021/cen-10135-buscon16\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Gilead Sciences is paying Assembly Biosciences $100 million for first refusal on all Assembly’s programs. The deal comprises $84.8 million in cash, plus $15.2 million in equity investment. Rather than buying the antiviral R&D firm outright, Gilead will integrate the company’s expertise in the herpes virus and hepatitis B and D. Assembly Bio will be responsible for early-stage research and development; if Gilead opts into any programs, it will take on all further work.\",\"PeriodicalId\":9517,\"journal\":{\"name\":\"C&EN Global Enterprise\",\"volume\":\"50 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-10-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"C&EN Global Enterprise\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1021/cen-10135-buscon16\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"C&EN Global Enterprise","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1021/cen-10135-buscon16","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Gilead Sciences is paying Assembly Biosciences $100 million for first refusal on all Assembly’s programs. The deal comprises $84.8 million in cash, plus $15.2 million in equity investment. Rather than buying the antiviral R&D firm outright, Gilead will integrate the company’s expertise in the herpes virus and hepatitis B and D. Assembly Bio will be responsible for early-stage research and development; if Gilead opts into any programs, it will take on all further work.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
